Power Law company profile

Atea Pharmaceuticals

Biotech & Life Sciences · Boston, United States · Founded 2014 · IPO 2020 Thoroughbred

Innovative oral antiviral therapies transforming treatments for serious viral diseases

Valuation

$140M

Market cap · May/2026

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

4 investors on Atea Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

RMI Partners

Series B+ 3 investors entered at this stage

Bain Capital Life Sciences

Perceptive Advisors

Omega Funds

Global footprint

Where Atea Pharmaceuticals has talent and traffic

AI talent share

1.8% of workforce is AI talent
(1 of 57 staff)

Core AI00%

Other AI11.75%

Non-AI workforce5698.25%

Workforce by country

2 countries with
team presence

🇺🇸 United States97.8%

🇧🇷 Brazil2.2%

2 countries shown

Web traffic by country

3K monthly visits
across markets

🇺🇸 United States100%

Top 1 markets shown

Market sentiment

What the market is saying about Atea Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Atea Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Atea Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles